While over 270 companies are doing artificial intelligence-driven drug development, many potential partners and investors are holding out for the first fruits of AI-based approaches. However, BenevolentAI Limited is being championed not only by investors, but by large pharma companies that have benefited from their work.
“There’s something happening in our sector,” said Ivan Griffin, co-founder and chief operating officer of the London, UK-headquartered biotech. “Investment and growth have slowed down and people are waiting to...